Satsuma Pharmaceuticals, a subsidiary of Shin Nippon Biomedical Laboratories (TYO:2395), has secured US FDA approval for Atzumi (dihydroergotamine nasal powder) to treat acute migraines in adults, according to a Thursday filing on the Tokyo Stock Exchange.
Developed using Shin Nippon Biomedical's unique intranasal delivery platform, Atzumi is the first FDA-approved nasal migraine treatment. The approval follows successful Phase 1 and Phase 3 trials.
Price (JPY): $1562.00, Change: $-3.0, Percent Change: -0.19%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。